Advertisement

Journal of Neuro-Oncology

, Volume 126, Issue 1, pp 175–183 | Cite as

Patterns of care in recurrent glioblastoma in Switzerland: a multicentre national approach based on diagnostic nodes

  • T. Hundsberger
  • A. F. Hottinger
  • U. Roelcke
  • P. Roth
  • D. Migliorini
  • P. Y. Dietrich
  • K. Conen
  • G. Pesce
  • E. Hermann
  • A. Pica
  • M. W. Gross
  • D. Brügge
  • L. Plasswilm
  • M. Weller
  • P. M. Putora
Clinical Study

Abstract

Despite moderate improvements in outcome of glioblastoma after first-line treatment with chemoradiation recent clinical trials failed to improve the prognosis of recurrent glioblastoma. In the absence of a standard of care we aimed to investigate institutional treatment strategies to identify similarities and differences in the pattern of care for recurrent glioblastoma. We investigated re-treatment criteria and therapeutic pathways for recurrent glioblastoma of eight neuro-oncology centres in Switzerland having an established multidisciplinary tumour-board conference. Decision algorithms, differences and consensus were analysed using the objective consensus methodology. A total of 16 different treatment recommendations were identified based on combinations of eight different decision criteria. The set of criteria implemented as well as the set of treatments offered was different in each centre. For specific situations, up to 6 different treatment recommendations were provided by the eight centres. The only wide-range consensus identified was to offer best supportive care to unfit patients. A majority recommendation was identified for non-operable large early recurrence with unmethylated MGMT promoter status in the fit patients: here bevacizumab was offered. In fit patients with late recurrent non-operable MGMT promoter methylated glioblastoma temozolomide was recommended by most. No other majority recommendations were present. In the absence of strong evidence we identified few consensus recommendations in the treatment of recurrent glioblastoma. This contrasts the limited availability of single drugs and treatment modalities. Clinical situations of greatest heterogeneity may be suitable to be addressed in clinical trials and second opinion referrals are likely to yield diverging recommendations.

Keywords

Recurrent glioblastoma Diagnostic nodes Objective consensus Decision making Re-treatment criteria 

Notes

Acknowledgments

TH, LP received honaria for advisory board lecture and travel grants from Roche and MSD. PR received honoraria for advisory board activities or lectures from MSD, Roche, Novartis and Molecular Partners. MW has received research grants from Acceleron, Actelion, Alpinia Institute, Bayer, Isarna, MSD, Merck & Co, Novocure, PIQUR and Roche and honoraria for lectures or advisory board participation or consulting from Celldex, Immunocellular, Isarna, Magforce, MSD, Merck & Co, Northwest Biotherapeutics, Novocure, Pfizer, Roche and Teva.

Compliance with ethical standards

Conflict of interest

AFH, UR, DM, PYD, KC, EH, AP, MWG, DB disclosed no conflict of interest.

Ethical standards

No specific patient data was used in this project.

Funding

The Department of Radiation Oncology (PMP) at the Cantonal hospital St. Gallen received a grant from Roche, Switzerland to perform this analysis.

References

  1. 1.
    Ostrom QT, Bauchet L, Davis FG, Deltour I, Fisher JL, Langer CE, Pekmezci M, Schwartzbaum JA, Turner MC, Walsh KM (2014) The epidemiology of glioma in adults: a “state of the science” review. Neuro-oncology 16:896–913PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Stupp R, Mason WP, Van Den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996PubMedCrossRefGoogle Scholar
  3. 3.
    Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370:699–708PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi ME, Jaeckle KA, Armstrong TS, Wefel JS, Won M, Blumenthal DT, Mahajan A, Schultz CJ, Erridge S, Baumert B, Hopkins KI, Tzuk-Shina T, Brown PD, Chakravarti A, Curran WJ Jr, Mehta MP (2013) Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. Journal of Clinical Oncology 31:4085–4091. doi: 10.1200/JCO.2013.49.6968 PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Stupp R, Hegi ME, Gorlia T, Erridge SC, Perry J, Hong Y-K, Aldape KD, Lhermitte B, Pietsch T, Grujicic D (2014) Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 15:1100–1108PubMedCrossRefGoogle Scholar
  6. 6.
    Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D (2014) Bevacizumab plus radiotherapy—temozolomide for newly diagnosed glioblastoma. N Engl J Med 370:709–722PubMedCrossRefGoogle Scholar
  7. 7.
    Wick W, Steinbach JP, Kuker WM, Dichgans J, Bamberg M, Weller M (2004) One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma. Neurology 62:2113–2115PubMedCrossRefGoogle Scholar
  8. 8.
    Brandes AA, Tosoni A, Cavallo G, Bertorelle R, Gioia V, Franceschi E, Biscuola M, Blatt V, Crino L, Ermani M, Gicno (2006) Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). Br J Cancer 95:1155–1160. doi: 10.1038/sj.bjc.6603376 PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Perry JR, Belanger K, Mason WP, Fulton D, Kavan P, Easaw J, Shields C, Kirby S, Macdonald DR, Eisenstat DD, Thiessen B, Forsyth P, Pouliot JF (2010) Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. Journal of Clinical Oncology 28:2051–2057. doi: 10.1200/JCO.2009.26.5520 PubMedCrossRefGoogle Scholar
  10. 10.
    Norden AD, Lesser GJ, Drappatz J, Ligon KL, Hammond SN, Lee EQ, Reardon DR, Fadul CE, Plotkin SR, Batchelor TT, Zhu JJ, Beroukhim R, Muzikansky A, Doherty L, Lafrankie D, Smith K, Tafoya V, Lis R, Stack EC, Rosenfeld MR, Wen PY (2013) Phase 2 study of dose-intense temozolomide in recurrent glioblastoma. Neuro-oncology 15:930–935. doi: 10.1093/neuonc/not040 PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Weller M, Tabatabai G, Kastner B, Felsberg J, Steinbach JP, Wick A, Schnell O, Hau P, Herrlinger U, Sabel MC, Wirsching HG, Ketter R, Bahr O, Platten M, Tonn JC, Schlegel U, Marosi C, Goldbrunner R, Stupp R, Homicsko K, Pichler J, Nikkhah G, Meixensberger J, Vajkoczy P, Kollias S, Husing J, Reifenberger G, Wick W, Group DS (2015) MGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: the DIRECTOR Trial. Clin Cancer Res 21:2057–2064. doi: 10.1158/1078-0432.CCR-14-2737 PubMedCrossRefGoogle Scholar
  12. 12.
    Wick W, Puduvalli VK, Chamberlain MC, van den Bent MJ, Carpentier AF, Cher LM, Mason W, Weller M, Hong S, Musib L (2010) Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 28:1168–1174PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Batchelor TT, Mulholland P, Neyns B, Nabors LB, Campone M, Wick A, Mason W, Mikkelsen T, Phuphanich S, Ashby LS (2013) Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol 31:3212–3218PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Weller M, van den Bent M, Hopkins K, Tonn JC, Stupp R, Falini A, Cohen-Jonathan-Moyal E, Frappaz D, Henriksson R, Balana C, Chinot O, Ram Z, Reifenberger G, Soffietti R, Wick W, European Association for Neuro-Oncology Task Force on Malignant G (2014) EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol 15:e395–e403. doi: 10.1016/S1470-2045(14)70011-7 PubMedCrossRefGoogle Scholar
  15. 15.
    Taal W, Oosterkamp HM, Walenkamp AM, Dubbink HJ, Beerepoot LV, Hanse MC, Buter J, Honkoop AH, Boerman D, de Vos FY, Dinjens WN, Enting RH, Taphoorn MJ, van den Berkmortel FW, Jansen RL, Brandsma D, Bromberg JE, van Heuvel I, Vernhout RM, van der Holt B, van den Bent MJ (2014) Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol 15:943–953. doi: 10.1016/S1470-2045(14)70314-6 PubMedCrossRefGoogle Scholar
  16. 16.
    Kreisl TN, Zhang W, Odia Y, Shih JH, Butman JA, Hammoud D, Iwamoto FM, Sul J, Fine HA (2011) A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma. Neuro-oncology 13:1143–1150PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M, Bigner DD, Friedman AH, Friedman HS (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13:1253–1259. doi: 10.1158/1078-0432.CCR-06-2309 PubMedCrossRefGoogle Scholar
  18. 18.
    Woernle CM, Peus D, Hofer S, Rushing EJ, Held U, Bozinov O, Krayenbuhl N, Weller M, Regli L (2015) Efficacy of surgery and further treatment of progressive glioblastoma. World Neurosurg. doi: 10.1016/j.wneu.2015.03.018 Google Scholar
  19. 19.
    Franceschi E, Bartolotti M, Tosoni A, Bartolini S, Sturiale C, Fioravanti A, Pozzati E, Galzio R, Talacchi A, Volpin L, Morandi L, Danieli D, Ermani M, Brandes AA (2015) The effect of re-operation on survival in patients with recurrent glioblastoma. Anticancer Res 35:1743–1748PubMedGoogle Scholar
  20. 20.
    Vuorinen V, Hinkka S, Farkkila M, Jaaskelainen J (2003) Debulking or biopsy of malignant glioma in elderly people—a randomised study. Acta Neurochir (Wien) 145:5–10. doi: 10.1007/s00701-002-1030-6 CrossRefGoogle Scholar
  21. 21.
    Fogh SE, Andrews DW, Glass J, Curran W, Glass C, Champ C, Evans JJ, Hyslop T, Pequignot E, Downes B, Comber E, Maltenfort M, Dicker AP, Werner-Wasik M (2010) Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. J Clin Oncol 28:3048–3053. doi: 10.1200/JCO.2009.25.6941 PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Mizumoto M, Okumura T, Ishikawa E, Yamamoto T, Takano S, Matsumura A, Oshiro Y, Ishikawa H, Sakurai H, Tsuboi K (2013) Reirradiation for recurrent malignant brain tumor with radiotherapy or proton beam therapy. Technical considerations based on experience at a single institution. Strahlenther Onkol 189:656–663. doi: 10.1007/s00066-013-0390-6 PubMedCrossRefGoogle Scholar
  23. 23.
    Gutin PH, Iwamoto FM, Beal K, Mohile NA, Karimi S, Hou BL, Lymberis S, Yamada Y, Chang J, Abrey LE (2009) Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 75:156–163. doi: 10.1016/j.ijrobp.2008.10.043 PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Wick W, Fricke H, Junge K, Kobyakov G, Martens T, Heese O, Wiestler B, Schliesser MG, von Deimling A, Pichler J, Vetlova E, Harting I, Debus J, Hartmann C, Kunz C, Platten M, Bendszus M, Combs SE (2014) A phase II, randomized, study of weekly APG101 + reirradiation versus reirradiation in progressive glioblastoma. Clin Cancer Res 20:6304–6313. doi: 10.1158/1078-0432.CCR-14-0951-T PubMedCrossRefGoogle Scholar
  25. 25.
    Hundsberger T, Brügge D, Putora PM, Weder P, Weber J, Plasswilm L (2013) Re-irradiation with and without bevacizumab as salvage therapy for recurrent or progressive high-grade gliomas. J Neurooncol 112:133–139PubMedCrossRefGoogle Scholar
  26. 26.
    Weller M, Cloughesy T, Perry JR, Wick W (2013) Standards of care for treatment of recurrent glioblastoma—are we there yet? Neuro-oncology 15:4–27PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Putora PM, Oldenburg J (2013) Swarm-based medicine. J Med Internet Res 15:e207. doi: 10.2196/jmir.2452 PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Putora PMBM, Papachristofilou A, Mariotti F, Paoli B, Plasswilm L (2010) Dodes (diagnostic nodes) for guideline manipulation. J Radiat Oncol Inf 2:1–8Google Scholar
  29. 29.
    Putora PM, Panje CM, Papachristofilou A, Dal Pra A, Hundsberger T, Plasswilm L (2014) Objective consensus from decision trees. Radiat Oncol 9:270PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.
    Rothermundt C, Bailey A, Cerbone L, Eisen T, Escudier B, Gillessen S, Grunwald V, Larkin J, McDermott D, Oldenburg J, Porta C, Rini B, Schmidinger M, Sternberg C, Putora PM (2015) Algorithms in the first-line treatment of metastatic clear cell renal cell carcinoma-analysis using diagnostic nodes. Oncologist 20:1028–1035. doi: 10.1634/theoncologist.2015-0145 PubMedCrossRefGoogle Scholar
  31. 31.
    Panje CM, Dal Pra A, Zilli T, Daniel RZ, Papachristofilou A, Herrera FG, Matzinger O, Plasswilm L, Putora PM (2015) Consensus and differences in primary radiotherapy for localized and locally advanced prostate cancer in Switzerland: a survey on patterns of practice. Strahlenther Onkol. doi: 10.1007/s00066-015-0849-8 Google Scholar
  32. 32.
    Batchelor TT, Mulholland P, Neyns B, Nabors LB, Campone M, Wick A, Mason W, Mikkelsen T, Phuphanich S, Ashby LS, Degroot J, Gattamaneni R, Cher L, Rosenthal M, Payer F, Jurgensmeier JM, Jain RK, Sorensen AG, Xu J, Liu Q, van den Bent M (2013) Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol 31:3212–3218. doi: 10.1200/JCO.2012.47.2464 PubMedCentralPubMedCrossRefGoogle Scholar
  33. 33.
    Wick W, Puduvalli VK, Chamberlain MC, van den Bent MJ, Carpentier AF, Cher LM, Mason W, Weller M, Hong S, Musib L, Liepa AM, Thornton DE, Fine HA (2010) Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 28:1168–1174. doi: 10.1200/JCO.2009.23.2595 PubMedCentralPubMedCrossRefGoogle Scholar
  34. 34.
    Weller M, Cloughesy T, Perry JR, Wick W (2013) Standards of care for treatment of recurrent glioblastoma–are we there yet? Neuro-oncology 15:4–27. doi: 10.1093/neuonc/nos273 PubMedCentralPubMedCrossRefGoogle Scholar
  35. 35.
    Mariniello G, Peca C, De Caro Mdel B, Giamundo A, Donzelli R, Maiuri F (2014) Glioblastoma in the elderly: the impact of advanced age on treatment and survival. J Neurol Surg A Cent Eur Neurosurg 75:276–281. doi: 10.1055/s-0033-1349713 PubMedCrossRefGoogle Scholar
  36. 36.
    Kirkpatrick JP, Sampson JH (2014) Recurrent malignant gliomas. Semin Radiat Oncol 24:289–298. doi: 10.1016/j.semradonc.2014.06.006 PubMedCentralPubMedCrossRefGoogle Scholar
  37. 37.
    Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for R, Treatment of Cancer Brain T, Radiotherapy G, National Cancer Institute of Canada Clinical Trials G (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. The New England journal of medicine 352:987–996. doi: 10.1056/NEJMoa043330 PubMedCrossRefGoogle Scholar
  38. 38.
    Chinot OL, de La Motte Rouge T, Moore N, Zeaiter A, Das A, Phillips H, Modrusan Z, Cloughesy T (2011) AVAglio: phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Adv Ther 28:334–340. doi: 10.1007/s12325-011-0007-3 PubMedCrossRefGoogle Scholar
  39. 39.
    Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross JG, Eisenhauer E, Belanger K, Brandes AA, Allgeier A, Lacombe D, Stupp R (2008) Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol 9:29–38. doi: 10.1016/S1470-2045(07)70384-4 PubMedCrossRefGoogle Scholar
  40. 40.
    Fiorentino A, Caivano R, Chiumento C, Cozzolino M, Clemente S, Pedicini P, Fusco V (2012) Comorbidity assessment and adjuvant radiochemotherapy in elderly affected by glioblastoma. Med Oncol 29:3467–3471. doi: 10.1007/s12032-012-0246-4 PubMedCrossRefGoogle Scholar
  41. 41.
    Balducci M, Fiorentino A, De Bonis P, Chiesa S, Manfrida S, D’Agostino GR, Mantini G, Frascino V, Mattiucci GC, De Bari B, Mangiola A, Micciche F, Gambacorta MA, Colicchio G, Morganti AG, Anile C, Valentini V (2012) Impact of age and co-morbidities in patients with newly diagnosed glioblastoma: a pooled data analysis of three prospective mono-institutional phase II studies. Med Oncol 29:3478–3483. doi: 10.1007/s12032-012-0263-3 PubMedCrossRefGoogle Scholar
  42. 42.
    Ackerl M, Flechl B, Dieckmann K, Preusser M, Widhalm G, Sax C, Marosi C (2014) Outcome evaluation in glioblastoma patients older than 65 years: importance of individual assessment of treatment tolerance. Clin Neuropathol 33:399–406. doi: 10.5414/NP300761 PubMedCrossRefGoogle Scholar
  43. 43.
    Bauchet L, Zouaoui S, Darlix A, Menjot de Champfleur N, Ferreira E, Fabbro M, Kerr C, Taillandier L (2014) Assessment and treatment relevance in elderly glioblastoma patients. Neuro-oncology 16:1459–1468. doi: 10.1093/neuonc/nou063 PubMedCentralPubMedCrossRefGoogle Scholar
  44. 44.
    Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ Jr, Mehta MP (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370:699–708. doi: 10.1056/NEJMoa1308573 PubMedCentralPubMedCrossRefGoogle Scholar
  45. 45.
    Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Abrey L, Cloughesy T (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370:709–722. doi: 10.1056/NEJMoa1308345 PubMedCrossRefGoogle Scholar
  46. 46.
    Park JK, Hodges T, Arko L, Shen M, Dello Iacono D, McNabb A, Olsen Bailey N, Kreisl TN, Iwamoto FM, Sul J, Auh S, Park GE, Fine HA, Black PM (2010) Scale to predict survival after surgery for recurrent glioblastoma multiforme. J Clin Oncol 28:3838–3843. doi: 10.1200/JCO.2010.30.0582 PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • T. Hundsberger
    • 1
  • A. F. Hottinger
    • 2
  • U. Roelcke
    • 3
  • P. Roth
    • 4
  • D. Migliorini
    • 5
  • P. Y. Dietrich
    • 5
  • K. Conen
    • 6
  • G. Pesce
    • 7
  • E. Hermann
    • 8
  • A. Pica
    • 8
  • M. W. Gross
    • 9
  • D. Brügge
    • 10
  • L. Plasswilm
    • 10
  • M. Weller
    • 4
  • P. M. Putora
    • 10
  1. 1.Department of Neurology and Department of Haematology/OncologyCantonal Hospital St. GallenSt. GallenSwitzerland
  2. 2.Department of Clinical Neurosciences & OncologyUniversity HospitalLausanneSwitzerland
  3. 3.Department of Neurology and Brain Tumour CentreCantonal Hospital AarauAarauSwitzerland
  4. 4.Department of Neurology, and Brain Tumor CentreUniversity HospitalZurichSwitzerland
  5. 5.Department of OncologyUniversity Hospital GenevaGenevaSwitzerland
  6. 6.Department of OncologyUniversity Hospital BaselBaselSwitzerland
  7. 7.Department of Radiation OncologyOncology Institute of Southern SwitzerlandBellinzonaSwitzerland
  8. 8.Department of Radiation OncologyUniversity Hospital BernBernSwitzerland
  9. 9.Department of Radiation OncologyUniversity Hospital BaselBaselSwitzerland
  10. 10.Department of Radiation OncologyCantonal Hospital St. GallenSt. GallenSwitzerland

Personalised recommendations